104121-92-8

104121-92-8 structure

Name: Eldecalcitol
Chemical Name: (1S,2S,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-2-(3-hydroxypropoxy)-4-methylidenecyclohexane-1,3-diol
CAS Number: 104121-92-8
Molecular Formula: C₃₀H₅₀O₅
Molecular Weight: 490.715
Catalog: Signaling Pathways Vitamin D Related VD/VDR
Create Date: 2018-12-17 12:06:41
Modify Date: 2024-01-02 10:30:02
Eldecalcitol (ED-71; 2.beta.-(3-Hydroxypropoxy)-1.alpha.,25-dihydroxyvitamin D3) is an analog of 1,25-dihydroxyvitamin D3 that improves bone mineral density. IC50 value:Target: Vd analogEldecalcitol (ED-71; 2.beta.-(3-Hydroxypropoxy)-1.alpha.,25-dihydroxyvitamin D3) is more efficacious than alfacalcidol in preventing vertebral and wrist fractures in osteoporotic patients with vitamin D sufficiency, with a safety profile similar to alfacalcidol.

Name	(1S,2S,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-2-(3-hydroxypropoxy)-4-methylidenecyclohexane-1,3-diol
Synonyms	HY-A0020 ED 71 9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol, 2-(3-hydroxypropoxy)-, (1α,2β,3β,5Z,7E)- UNII-I2JP8UE90H Eldecalcitol CS-0363 1,3-Cyclohexanediol, 2-(3-hydroxypropoxy)-4-methylene-5-[(2E)-2-[(1R,3aS,7aR)-octahydro-1-[(1R)-5-hydroxy-1,5-dimethylhexyl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-, (1R,2R,3R,5Z)- 1α,25-dihydroxy-2β-(3-hydroxypropoxy)vitamin D3 (1R,2R,3R,5Z,7E)-2-(3-Hydroxypropoxy)-9,10-secocholesta-5,7,10-triene-1,3,25-triol

Description	Eldecalcitol (ED-71; 2.beta.-(3-Hydroxypropoxy)-1.alpha.,25-dihydroxyvitamin D3) is an analog of 1,25-dihydroxyvitamin D3 that improves bone mineral density. IC50 value:Target: Vd analogEldecalcitol (ED-71; 2.beta.-(3-Hydroxypropoxy)-1.alpha.,25-dihydroxyvitamin D3) is more efficacious than alfacalcidol in preventing vertebral and wrist fractures in osteoporotic patients with vitamin D sufficiency, with a safety profile similar to alfacalcidol.
Related Catalog	Signaling Pathways >> Vitamin D Related >> VD/VDR Research Areas >> Others
References	[1]. Matsumoto T.Osteoporosis Treatment by a New Active Vitamin D3 Compound, Eldecalcitol, in Japan.Curr Osteoporos Rep. 2012 Aug 24. [2]. Shiraki M, et al. Eldecalcitol normalizes bone turnover markers regardless of their pre-treatment levels.Curr Med Res Opin. 2012 Aug 23. [3]. Matsumoto T, Endo I.Eldecalcitol for the treatment of osteoporosis.Drugs Today (Barc). 2012 Mar;48(3):189-96. [4]. Sakai S, et al.Combination therapy with eldecalcitol and alendronate has therapeutic advantages over monotherapy by improving bone strength.Bone. 2012 May;50(5):1054-63. Epub 2012 Feb 17. [5]. Sanford M, McCormack PL.Spotlight on eldecalcitol in osteoporosis.Drugs Aging. 2012 Jan 1;29(1):69-71.